PMID- 37831068
OWN - NLM
STAT- MEDLINE
DCOM- 20240103
LR  - 20240206
IS  - 1557-3125 (Electronic)
IS  - 1541-7786 (Print)
IS  - 1541-7786 (Linking)
VI  - 22
IP  - 1
DP  - 2024 Jan 2
TI  - RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and 
      Metastatic Potential.
PG  - 41-54
LID - 10.1158/1541-7786.MCR-23-0512 [doi]
AB  - RNF185 is a RING finger domain-containing ubiquitin ligase implicated in 
      ER-associated degradation. Prostate tumor patient data analysis revealed a 
      negative correlation between RNF185 expression and prostate cancer progression 
      and metastasis. Likewise, several prostate cancer cell lines exhibited greater 
      migration and invasion capabilities in culture upon RNF185 depletion. 
      Subcutaneous inoculation of mouse prostate cancer MPC3 cells stably expressing 
      short hairpin RNA against RNF185 into mice resulted in larger tumors and more 
      frequent lung metastases. RNA-sequencing and Ingenuity Pathway Analysis 
      identified wound-healing and cellular movement among the most significant 
      pathways upregulated in RNF185-depleted lines, compared with control prostate 
      cancer cells. Gene Set Enrichment Analyses performed in samples from patients 
      harboring low RNF185 expression and in RNF185-depleted lines confirmed the 
      deregulation of genes implicated in epithelial-to-mesenchymal transition. Among 
      those, COL3A1 was identified as the primary mediator of RNF185's ability to 
      impact migration phenotypes. Correspondingly, enhanced migration and metastasis 
      of RNF185 knockdown (KD) prostate cancer cells were attenuated upon co-inhibition 
      of COL3A1. Our results identify RNF185 as a gatekeeper of prostate cancer 
      metastasis, partly via its control of COL3A1 availability. IMPLICATIONS: RNF185 
      is identified as an important regulator of prostate cancer migration and 
      metastasis, in part due to its regulation of COL3A1. Both RNF185 and COL3A1 may 
      serve as novel markers for prostate tumors.
CI  - (c)2023 American Association for Cancer Research.
FAU - Van Espen, Benjamin
AU  - Van Espen B
AUID- ORCID: 0000-0003-1587-4942
AD  - Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
      California.
FAU - Oo, Htoo Zarni
AU  - Oo HZ
AUID- ORCID: 0009-0009-8514-2713
AD  - Department of Urologic Sciences, Vancouver Prostate Centre, University of British 
      Columbia, Vancouver, Canada.
FAU - Collins, Colin
AU  - Collins C
AUID- ORCID: 0000-0001-6148-6110
AD  - Department of Urologic Sciences, Vancouver Prostate Centre, University of British 
      Columbia, Vancouver, Canada.
FAU - Fazli, Ladan
AU  - Fazli L
AUID- ORCID: 0009-0005-0731-0583
AD  - Department of Urologic Sciences, Vancouver Prostate Centre, University of British 
      Columbia, Vancouver, Canada.
FAU - Molinolo, Alfredo
AU  - Molinolo A
AUID- ORCID: 0000-0001-8412-2889
AD  - Department of Pathology, University of California San Diego, La Jolla, 
      California.
FAU - Yip, Kevin
AU  - Yip K
AUID- ORCID: 0000-0001-5516-9944
AD  - Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
      California.
FAU - Murad, Rabi
AU  - Murad R
AUID- ORCID: 0009-0004-5297-8307
AD  - Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
      California.
FAU - Gleave, Martin
AU  - Gleave M
AUID- ORCID: 0000-0003-4235-0167
AD  - Department of Urologic Sciences, Vancouver Prostate Centre, University of British 
      Columbia, Vancouver, Canada.
FAU - Ronai, Ze'ev A
AU  - Ronai ZA
AUID- ORCID: 0000-0002-3859-0400
AD  - Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 
      California.
LA  - eng
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R35 CA197465/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Mol Cancer Res
JT  - Molecular cancer research : MCR
JID - 101150042
RN  - 0 (RNA, Small Interfering)
RN  - 0 (COL3A1 protein, human)
RN  - 0 (Collagen Type III)
RN  - EC 2.3.2.27 (RNF185 protein, human)
RN  - 0 (Mitochondrial Proteins)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
UOF - bioRxiv. 2023 Jul 01;:. PMID: 37425866
MH  - Male
MH  - Humans
MH  - Mice
MH  - Animals
MH  - *Prostatic Neoplasms/pathology
MH  - Prostate/pathology
MH  - Cell Movement/genetics
MH  - Epithelial-Mesenchymal Transition
MH  - RNA, Small Interfering
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic
MH  - Collagen Type III/genetics/metabolism
MH  - Mitochondrial Proteins/genetics
MH  - Ubiquitin-Protein Ligases/genetics/metabolism
PMC - PMC10841372
MID - NIHMS1939064
EDAT- 2023/10/13 12:42
MHDA- 2024/01/03 09:43
PMCR- 2024/07/02
CRDT- 2023/10/13 11:04
PHST- 2023/06/29 00:00 [received]
PHST- 2023/09/19 00:00 [revised]
PHST- 2023/10/11 00:00 [accepted]
PHST- 2024/07/02 00:00 [pmc-release]
PHST- 2024/01/03 09:43 [medline]
PHST- 2023/10/13 12:42 [pubmed]
PHST- 2023/10/13 11:04 [entrez]
AID - 729588 [pii]
AID - 10.1158/1541-7786.MCR-23-0512 [doi]
PST - ppublish
SO  - Mol Cancer Res. 2024 Jan 2;22(1):41-54. doi: 10.1158/1541-7786.MCR-23-0512.